Limbaga, Bb Boy .
HRN: 27-35-92 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/26/2025
MUPIROCIN 2%, 15G (TUBE)
06/26/2025
07/02/2025
TOPICAL
Thin Layer
TID
IV Site Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes